CyPath Lung Test Sales Surge 146% in Q1 2026, Driven by Physician Adoption
Event summary
- CyPath Lung test unit sales grew 146% year-over-year in Q1 2026, exceeding internal projections.
- 2025 revenue increased 87% year-over-year, with test units sold growing 99% compared to 2024.
- The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients.
- The U.S. addressable market for CyPath Lung is projected to reach $3.58 billion by 2030.
The big picture
The surge in CyPath Lung sales reflects growing physician recognition of its value in early lung cancer detection, addressing a critical gap in the diagnostic pathway. The expanding patient population with indeterminate pulmonary nodules and the increasing number of lung cancer survivors present a significant market opportunity. bioAffinity's focused commercial strategy and ongoing clinical studies position CyPath Lung for continued growth in a market projected to reach $3.58 billion by 2030.
What we're watching
- Market Penetration
- Whether bioAffinity can sustain the rapid adoption pace of CyPath Lung among pulmonologists and other ordering physicians.
- Clinical Validation
- The impact of ongoing longitudinal studies on further validating CyPath Lung's clinical utility and expanding its use cases.
- Regulatory Environment
- How changes in the regulatory landscape for laboratory-developed tests could affect bioAffinity's commercial strategy.
Related topics